Makary talks FDA's plans to combat China's biotech growth
马卡里谈FDA遏制manbetx3.0 生物技术增长的计划

As China sees increased biotech investments, licensing deals and faster early-phase clinical trial starts, FDA Commissioner Marty Makary said his agency is reworking Phase 1 trial regulations to speed that entry process and tweaking user fees to encourage R&D in the US.
随着manbetx3.0 的生物技术投资、许可交易增多以及早期临床试验启动加快，FDA局长马蒂•马卡里表示，该机构正在修订一期临床试验法规以加速准入进程，并调整用户费以鼓励在美国开展研发。